Advances in the treatment of relapsing-remitting multiple sclerosis - Critical appraisal of fingolimod

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 73-85

  Gasperini, Claudio ^a   Ruggieri, Serena ^b   Mancinelli, Chiara Rosa ^b   Pozzilli, Carlo ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adherence; Fingolimod; Multiple sclerosis; Oral compounds; Patient satisfaction; Sphingosine 1 phosphate

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; LAQUINIMOD; PLACEBO; RECOMBINANT BETA INTERFERON; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TERIFLUNOMIDE;

AIRWAY OBSTRUCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANKLE EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BACKACHE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN HEMORRHAGE; BUDD CHIARI SYNDROME; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; IMAGE ENHANCEMENT; IMMUNOMODULATION; LARYNX PAIN; LIMB PAIN; LYMPHOCYTOPENIA; MEAN ARTERIAL PRESSURE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SORE THROAT;

EID: 84875416606     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S17426     Document Type: Review

References (56)

1. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129-135.
2. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525-527.
3. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
4. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606-616.
5. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210-218.
6. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006;354:942-955.
7. Pozzilli C, Schweikert B, Ecari U. BetaPlus Study group. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis - results of the βPlus observational cohort study. J Neurol Sci. 2011;307: 120-126.
8. US Food and Drug Administration. FDA approves first oral drug to reduce MS relapses [press release]. Silver Spring, MD, USA: FDA; September 22, 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm. Accessed November 19, 2012.
9. Therapeutic Goods Administration. Therapeutic Goods Administration. Australian Public Assessment Report for Cladribine Tablets. Woden, ACT, Australia: TGA; 2011. Available from: http://www.tga.gov.au/pdf/auspar/auspar-movectro.pdf. Accessed November 19, 2012.
10. Giovannoni G, Comi G, Cook S, et al. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362: 416-426.
11. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (Cladribine Tablets Treating Multiple Sclerosis Orally) study. Mult Scler. 2011;17:578-593.
12. Lukashev M, Zeng W, Ryan S, et al. Activation of Nrf 2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Mult Scler. 2007;13:S149.
13. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo controlled phase IIb study. Lancet. 2008;372:1463-1472.
14. Gold R, Kappos L, Bar-Or A, et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. Mult Scler J. 2011;17:95.
15. Arnold D, Gold R, Bar-Or A, et al. Efficacy on MRI endpoints of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. Mult Scler J. 2011;17:P813.
16. Fox R, Miller D, Phillips JT, et al. Clinical efficacy of BG-12 in relapsing-remitting multiple sclerosis (RRMS): data from the phase 3 CONFIRM study. Neurology. 2012;78:S01.00.
17. Warnke C, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333-340.
18. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain. 2001;124:1791-1802.
19. Merril JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 2009;256:89-103.
20. O'Connor PW, Li D, Freedmann MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
21. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18:1278-1289.
22. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-1303.
23. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-- 215062) suppresses the development of experimental autoimmune encephalomyelitis, the Th1/Th2 balance and induces the Th3 cytokine TGFβ in Lewis rats. J Neuroimmunol. 2004;156:3-9.
24. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-2092.
25. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000-1009.
26. Vollmer T, Comi G, Sorensen PS, et al. Clinical efficacy of laquinimod for the treatment of multiple sclerosis; pooled analyses from the ALLE-GRO and BRAVO phase III trials. Neurology. 2012;78:S01.007.
27. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173-1182.
28. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469-475.
29. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912-2921.
30. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994;47:208-215.
31. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 1994;33: 91-101.
32. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev. 2008;60:181-195.
33. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92:913-922.
34. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-- 1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117:77-93.
35. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105.
36. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8:1295-1301.
37. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321-354.
38. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082-9089.
39. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004;44:532-537.
40. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1083.
41. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005;2:439-448.
42. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003;305:70-77.
43. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;14;355: 1124-1140.
44. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;6;72:73-79.
45. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197-207.
46. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362: 402-415.
47. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362: 387-401.
48. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58:840-846.
49. Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008;66:199-206.
50. Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology. 2009;17;72:1022-1024.
51. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR__Conditions_imposed_on_member_states_for_safe_and_effective_use/human/002202/WC500104527.pdf.
52. Kasper LH, Due BR et ONO-4641 Study Group. A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no P991]. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; October 13-16, 2010; Gothenburg, Sweden.
53. Comi G, Kappos L, Palace J, et al. Cardiac safety of fingolimod 0.5 mg during the first dose observation in 4-month, open-label, multi-center FIRST study in patients with relapsing MS. Neurology. 2012;78: S41.003.
54. Geissbühler Y, Butzkueven H, Hernández-Diaz S, et al. Multinational Gilenya (fingolimod) pregnancy exposure registry in multiple sclerosis: study design. Neurology. 2012;78:P06.189.
55. European Medicines Agency. European Medicines Agency starts review of Gilenya (fingolimod). 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/01/human_pha_detail_000050.jsp&mid=WC0b01ac058001d126. Accessed November 19, 2012.
56. European Medicines Agency. Questions and answers on the review of Gilenya. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf. Accessed November 19, 2012.